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ABSTRACT 
Setting: Directly Observed Treatment Short-course is a key pillar of the global strategy 
to end tuberculosis.  
Objective: The effectiveness of community-based compared to facility-based DOTS on 
tuberculosis treatment success rates in Namibia was assessed. 
Methods: Annual tuberculosis treatment success, cure, completion and case notification 
rates were compared between 1996 and 2015 by interrupted time series analysis. The 
intervention was the upgrading by the Namibian government of the tuberculosis 
treatment strategy from facility-based to community-based DOTS in 2005.  
Results: The mean annual treatment success rate during the pre-intervention period 
was 58.9% (range: 46-66%) and significantly increased to 81.3% (range: 69-87%) 
during the post-intervention period. Before the intervention there was a non-significant 
increase (0.3%/year) in the annual treatment success rate. After the intervention, the 
annual treatment success rate increased abruptly by 12.9% (p <0.001) and continued to 
increase by 1.1%/year thereafter. The treatment success rate seemed to have 
stagnated at approximately 85% at the end of the observation period. 
 
Conclusion: Expanding facility-based DOTS to community-based DOTS significantly 
increased the annual treatment success rates. However, the treatment success rate at 
the end of the observation period had stagnated below the targeted 95% success rate.  
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INTRODUCTION 
 
Tuberculosis (TB) remains a significant health problem in many lower and 
middle-income countries. In 2015, there were 10.4 million cases of TB worldwide, 
leading to an estimated 1.8 million fatalities.1 The disease is particularly prevalent in 
Sub-Saharan African countries such as Namibia, where the case notification rate (CNR, 
i.e. the number of new and relapse TB cases notified in a year) was 489 cases per 
100,000 people in 2015.2 A major strategy to reduce TB incidence has been Directly 
Observed Treatment Short-course (DOTS), which was implemented in Namibia in 1995. 
Directly observed treatment (DOT), i.e standardized anti-TB drug regimens 
administered to patients under direct observation, remains a critical strategic goal of 
DOTS implementation in Namibia.3,4  
TB case identification and optimization of treatment outcomes through DOTS are 
the key global strategies to ³Hnd TB´LQ Namibia by 2035.1,4 Unsuccessful treatment 
outcomes however, are important risk factors for the development of drug-resistant TB, 
a condition that is extremely difficult and expensive to treat.5-9 In the past decade the 
community-based DOTS has improved treatment outcomes globally and in Namibia.9,10 
Nevertheless, Namibia, an upper-middle income country in southern Africa with a 
population of 2.2 million, remains one of the countries with the highest incidence of TB 
in the world.1,2,10 Therefore, facility-based DOTS (FB-DOTS) was scaled-up to all public 
health facilities in Namibia between 1991-1995 as a strategy to control TB and to 
improve treatment outcomes. 10, 11 In Namibia, FB-DOTS refers to when directly 
observed therapy and related services were only accessible at a health facility before 
2005, and CB-DOTS is when DOTS services were extended to villages and households 
through community based health workers. An assessment of the FB-DOTS strategy in 
Namibia in 2002 showed that, since its introduction in 1991-1995, TB incidence rates 
had not declined and treatment success rate (TSR, i.e. the proportion of cases cured or 
completed TB treatment in a given year) was at its lowest in 2004.10 As a result, the 
facility-based DOTS was scaled-up to community-based DOTS (CB-DOTS) under the 
first national TB and Leprosy Medium Term Plan I (MTP-I) implemented from 2004 - 
2009.12 The access to high quality CB-DOTS was further expanded, i.e to all regions, 
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public-private workplaces and integrated with community-based HIV (Human 
immunodeficiency virus) care and enhanced i.e improved quality of bacteriological 
assessments and the standardization of DOTS services such as treatment, DOT 
support, among others under MTP-II (2010-2016) to empower DOT supporters within 
each community to deliver quality DOT services.13,14 The targets for treatment success 
rate under MTP-I and MTP-II were 85% and 90%, respectively.12,13  
With the implementation of MTP-I in 2004, an electronic TB data base was 
started to closely monitor treatment outcomes. The objective of this study was to use 
the annual rates of treatment success, cure, treatment completion, before (1996-2004) 
and after (2005-2015) the implementation of MTP, to assess the effectiveness of CB-
DOTS to improve TB treatment outcomes.  
 
 
METHODS 
 
Data collection 
 
Quantitative population level data on annual TB rates of treatment success, cure 
(i.e. the proportion of  cases with pulmonary (PTB), that is TB with lung parenchyma 
involvement, with bacteriologically confirmed TB at the start of treatment whose sputum 
was smear- or culture-negative in the last month of treatment), treatment completion 
(i.e. the proportion of TB cases in a given year that successfully completed TB 
treatment without bacteriological evidence of success), and case notification for all 
cases of TB registered during the period 1995 to 2015 were extracted from the annual 
reports of the National Tuberculosis and Leprosy Programme (NTLP) of the Ministry of 
Health and Social Services (MOHSS) of Namibia.11 In Namibia treatment success for 
extra-pulmonary TB (EPTB, i.e TB disease at sites other than the lung parenchyma) is 
reported as the proportion of cases with/without aspirate bacteriological or 
cytology/histology results who are clinically well after completion of 6-8 months of 
treatment.11 The National Institute of Pathology, an accredited laboratory performs all 
the bacteriological testing for TB cases in all DOTS sites in Namibia. Consequently, a 
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case of cure is confirmed by a medical officer base on TB guidelines, which are 
implemented at all DOT sites with supported training. These annual rates are based on 
aggregates of quarterly reports collated from district and regional TB case registers. The 
annual rates were validated against the WHO Analytical Country Summaries for TB, as 
well as the data reported by the World Bank, United States Agency of International 
Development (USAID) and Global Fund.1 Twenty validated annual TSR, CNR from 
1995/1996 ± 2014/2015 for cases with PTB, EPTB, drug susceptible TB (DST) and drug 
resistant TB (DR-TB) were included in the study. Annual rates reported before 1995 
were excluded since there was no systematic reporting on TB outcomes before the 
establishment of the NTLP programme in 1991.10,11  
During the study period, the case definitions for cure and treatment completion did not 
change and the DOTS services were free of cost and treatment support as the only 
incentive during CB-DOTS. 
 
 Statistical analysis 
 
 An interrupted time series (ITS) analysis was conducted to establish the 
underlying trend in tuberculosis treatment success, cure and completion rates for all TB 
cases during the period 1996-2015. The effect of implementation of a country-wide 
community-based DOTS in Namibia in 2005, i.e. the intervention, on the treatment 
success, cure, and completion rates was also assessed by ITS.15 The interrupted time 
series analysis is explained in more detail in Supplement A. A comprehensive 
description of the implementation of facility-based DOTS in Namibia and the scale-up to 
community-based DOTS under the first and second National TB and Leprosy Medium 
Term Plans (MTP-I) and MTP-II) can be found in Supplement B.  
Ethics 
 
Data reported in public documents by the health authorities of Namibia were 
used as the primary source to assess the effectiveness of an intervention at the 
population level. Ethical approval for the study was obtained from the human ethics 
committees of the MOHSS and the University of Namibia. 
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RESULTS 
 
 The annual number of case notifications by TB category and the TSR, CNR, and 
population covariates from 1996 to 2015 are shown in Figures 1 and 2, respectively.  
 
 
Figure 1: Annual number of cases of drug susceptible tuberculosis (DST-TB, z), drug resistant 
tuberculosis (MDR-TB, S), multi-drug resistant tuberculosis (MDR-TB, ), pulmonary 
tuberculosis (PTB, ) and extrapulmonary tuberculosis (EPTB, {), during the period 1996-
2015. 
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Figure 2: Annual case notification rates (CNR,|), CB-DOTS coverage (), adult HIV 
prevalence (ª), ART coverage (U) and prevalence of HIV among TB patients (½), and 
treatment success rate (TSR, z) during the period 1996-2015. Data source: Annual 
MoHSS National TB and Leprosy reports, Global TB reports and WHO TB database1,2 
 
The mean (r SD) treatment success rate during the pre-intervention period was 58.9 r 
6.9% but varied considerably from year to year (range: 46% to 66%) (Figure 2). After 
implementation of CB-DOTS in 2005, a slow but steady increase in the annual TSR was 
observed: during MTP-I it was on average 76.4 r 4.8 % and during MTP-II 85.3 % r 
1.4% (p<0.001). During the post CB-DOTS implementation period, the mean annual 
TSR was significantly higher than during the pre-intervention period. After the 
implementation of the CB-DOTS strategy, the CNR, which had been around 
800/100,000 just before the intervention, started to gradually decline to 436/100,000 in 
2015. A significant inverse correlation (r = -0.65, p=0.001) was found between the CNR 
and the TSR. 
 The results of the final, i.e. after correction for autocorrelation, segmented 
regression model of the TSR, CNR, cure and treatment completion rates for all cases 
with drug susceptible TB are summarized in Table 1 and Figure 3a. The model 
estimated TSR at the beginning of the pre-intervention period (E0) at 58.0% and the 
CNR at 596.7/100,000. During the pre-intervention period the annual change in TSR, 
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CNR and cure rate (E1) was positive, indicating an increase in trend, which was only 
statistically significant for cure rate (p= 0.0172). The treatment completion rate during 
the pre-intervention period showed a slight, non-significant decrease. On the contrary, 
during the pre-intervention period, the CNR increased significantly by 23.9/100,000 
cases/year. After the intervention, the treatment success and treatment completion 
rates (E2) increased abruptly and significantly (p<0.001) by 12.9% and 24.3%, 
respectively, from the estimated level at the end of the pre-intervention period, e.g. from 
60.9% to 68.0% for TSR (Figure 3a). In contrast, the cure rate abruptly dropped after 
the CB-DOTS intervention by 18.6% (p<0.001). The immediate post-intervention 
change in the CNR was not statistically significant (Table 1). After the intervention, the 
trend in the annual TSR, cure and completion rates (E3) increased, but this was only 
statistically significant for TSR and cure rate. The post-intervention trend of CNR 
significantly decreased by 60.6/100,000 notifications per year. The wild point (i.e. 
unexpected and unexplained drop in TSR) at 2004 was associated with a significant 
drop in treatment success and cure rates (p<0.001), but not treatment completion rate 
(Figure 3a).  
  
9 
 
 
 
Figure 3: Interrupted time series analysis of the annual treatment success rate (), cure 
rate (z), and treatment completion rate ().The predicted pre- and post-intervention 
trends, based on the final segmented regression model, are shown by the lines.  
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Table 1: Estimated coefficients for the interrupted time series analysis of treatment 
success rate (TSR), cure rate, treatment completion and case notification rate (CNR). 
 
 
            After the intervention there was a significant (p<0.005) immediate increase in 
level and/or annual rates for treatment outcomes for pulmonary versus extrapulmonary 
(Figure 3c-d, Table 1) and DST-TB versus DR-TB (Figure 3a-b, Table 1) and the 
different classes of PTB categories, i.e. new smear positive, retreatment and smear 
negative cases (Table 1, Figure 4a-d).  
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Figure 4: Interrupted time series analysis of the annual treatment success rates 
(¡), cure rates (z), and treatment completion rates () by PTB categories, i.e. new 
smear positive cases, retreatment cases and negative smear patients. The predicted 
pre- and post-intervention 
 
Table 2 shows the impact of population covariates on TSR, cure and completion rates. 
During the post-intervention period, the increased national CB-DOTS and/or ART 
coverage significantly increased the TSR for all TB cases (Table 2). The impact of time 
varying covariates on treatment, cure and treatment completion rates for all TB cases 
was more significant with increased CB-DOTS and ART coverage (Table 2). HIV 
prevalence significantly reduced TSR, cure and completion rates among cases with 
DST-TB by 4.4%, 3.0% and 2.9%, respectively. The declining CNR had virtually no 
impact on treatment outcomes, but marginally increased the treatment completion rates 
among PTB and DST-TB.  
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Table 2: Impact of population time varying co-variates on treatment success, cure, 
treatment completion and case notification rates 
 
 
  
After the intervention the annual treatment success rate seemed to increase non-
linearly and tended towards a maximum which was estimated at 92.4% (95% CI: 87.7% 
- 97.1% r2: 0.961) current interventions (Supplement C, Figure 5). However, the 
approach to this estimated maximum treatment rate is very slow with a 90% treatment 
success rate estimated to be reached in 2025.  
 
DISCUSSION 
 
Directly observed therapy, as recommended by the World Health Organization, is 
used in many countries to deliver TB treatment.3,4,6 The effectiveness of community-
based versus facility-based (or clinic) DOTS has not been systematically assessed to 
date. Wright et al. performed a review and meta-analysis of 8 studies, carried out before 
2015, comparing treatment outcomes of CB-DOTS versus FB-DOTS.9 They concluded 
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that CB-DOTS had a higher treatment success rate with a pooled odds ratio of 1.54 
(95% confidence interval: 1.01 ± 2.36; p = 0.046). FB-DOTS was introduced in Namibia 
in 1991 and was universally accessible at all public health facilities in 1996, and was 
later expanded in 2005, to CB-DOTS. Before implementation of CB-DOTS, the annual 
TSR in Namibia was around 60% but showed high variability from year to year (range: 
46% to 66%). During the same period, the CNR slowly increased from 652/100,000 to 
822/100,000 population, which is among the highest in the world.2 The first year after 
the introduction of CB-DOTS, the TSR and completion rate, but not cure rate, showed a 
significant increase compared to the pre-intervention success rate level.  A review of 
MTP-I in 2010 attributed the sub-optimal cure rates to persistence of inadequate access 
to quality TB diagnostic services and direct observation of TB treatment due to the 
geographic vastness of the country (second lowest population density in the world) 
impeding not only patients level CB-DOTS coverage but also the quality and turn-
around time of TB direct microscopy results in remote areas and among highly mobile 
populations.12 The introduction of the electronic TB database in 2005 as a component of 
CB-DOTS may have increased the reporting of treatment outcomes which may explain 
the abrupt rise in TSR between 2004 and 2005. During the post-intervention period, 
treatment success rates continuously increased by 1.1%/year from 69% in 2005 to 88% 
at the end of 2015.  
Time varying covariates such as CB-DOTS coverage, HIV prevalence and ART 
coverage only marginally affected the TB treatment outcome rates for all TB cases. 
However, the effect of other potentially important covariates such as quality and 
availability of anti-TB medicines and drug-resistance patterns could not be tested due to 
the lack of proper data. Not surprisingly, the improvement of TSR after the 
implementation of CB-DOTS alongside other MTP interventions was accompanied by a 
gradual decrease in the CNR from 822/100,000 at the end of the pre-intervention period 
to 436/100,000 ten years later. This decrease in the annual CNR was inversely 
correlated to the treatment success rate (r2 = 0.46; p = 0.0011), but other factors such 
as improved programmatic detection of new TB cases and preventative control 
measures through community-based TB care as well as the improved access to quality 
DOTS services nationwide. However, the improvement of the treatment outcome rates 
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following the expansion of FB-DOTS to CB-DOTS falls short of the targets set by the 
NLTP/MOHSS under MTPI& II. The targets for treatment success rate under MTP-I and 
MTP-II were 85% and 90%, respectively. Although the target of the MTP-I programme 
was met, at the end of 2015 the treatment rate had seemingly stagnated around 
approximately 85%, which falls short of the MTP-II target of 95%. Even if the success 
rate would still have continued to increase during that final year, at the projected 
1.1%/year, the 90% target would still not have been reached. Moreover, the success 
rate data are clearly leveling off towards the end of the MTP-II programme. Based on 
the data, it would still take several decades to reach the predicted theoretical maximum 
success rate of approximately 92%.  
It is clear that the community-based DOTS strategy alone will not be able to ³end 
TB´. Other factors which cannot be controlled by community-based DOTS must be 
explaining why the treatment success rates are stagnating around 90%. Similar studies 
in other countries have concluded that stagnation of treatment success rates below the 
95% target may favour drug resistant TB and recommend modifications to the DOTS 
strategy.16-19 In low to middle income countries like Namibia, the effectiveness of DOTS 
is compromised by false negative smear results, the limited monitoring of bacteriological 
end points, and the growing burden of drug-resistant TB.20-24 Consequently, community-
based DOTS should be improved by implementing additional strategies to identify 
patients at risk of poor treatment outcomes WRUHDFK:+2¶VJRDOWR³HQG7%´E\. 
These additional community-based measures should focus on ways to improve 
treatment monitoring and outcomes in TB patients with co-morbidities such as HIV 
infection and diabetes, in childhood TB, in malnourished patients and other or mobile 
patient groups with an increased risk of treatment failure.17,21,25-30 In addition, the use of 
treatment completion as a surrogate measure of treatment success should be validated 
across all TB cases in the context of programmatic challenges. In addition, some 
communities/patients may require personalized rather than standardized DOTS 
approaches to optimise treatment outcomes.  
In conclusion, the results of this study demonstrate that community-based DOTS 
is more effective than facility-based DOTS to increase the TB treatment success rate. In 
Namibia, the community-based DOTS strategy, however, was not, and will not be, able 
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to reach the target of 95% success rate. Additional measures such as bacteriologic 
monitoring among patients at risk of therapeutic failure, is critical WR³HQG7%´E\ 
We are currently exploiting the extensive electronic TB database of the NLTP/MOHSS 
in an attempt to identify significant predictors of poor TB treatment outcome in Namibia.  
 
Acknowledgements 
 
The authors wish to acknowledge the assistance rendered by the staff at the National 
Tuberculosis and Leprosy Programme, Ministry of Health and Social Services Namibia 
in accessing of the data from the TB registers.  
The authors declare no conflict of interest. This study did not receive any specific grant 
from any funding agency in the public, commercial or non-profit sectors. Dr. Law 
received salary support through a Canada Research Chair and Michael Smith 
Foundation for Health Research Scholar Award. 
 
References 
 1. World Health Organization. Global Tuberculosis Report - 2016.  
     WHO/HTM/TB/2016.13, Geneva, Switzerland. 
 2. Republic of Namibia Ministry of Health and Social Services. National Tuberculosis 
     and Leprosy Programme Annual Report: 2014-2015, Windhoek, Namibia.  
 3. Raviglione M C, Uplekar M ::+2¶VQHZ67237%6WUDWHJ\7KH/DQFHW 
     367 (9514): 952-955. 
 4. World Health Organization. The Stop TB Strategy ± Building on and enhancing 
     DOTS to meet the TB-related Millennium Development Goals.  
     WHO/HTM/STB/2006.37, Geneva, Switzerland. 
 5. Lew P, Pai M, Oxlkade O, et al. Initial drug resistance and tuberculosis outcomes:  
     systematic review and meta-analysis. Ann Intern Med 2008; 149: 123-134.  
 6. Faustini A, Hall A J, Perucci C A. Tuberculosis treatment outcomes in Europe: a  
     systematic review. Eur Respir J 2005; 26: 503-510. 
 7. Sesay M L. Patient characteristics and treatment outcomes among tuberculosis  
     patients in Sierra Leone. Walden University 2017. 
  
16 
 8. Hung C L, Chien JY, Ou C Y. Associated factors for tuberculosis recurrence in  
     Taiwan: a nationwide nested case-control study from 1998 to 2010. PLoS One 2015; 
     10: e0124822. 
 9. Wright C M, Westerkamp L, Korver S, Dobler C C. Community-based directly  
     observed therapy (DOT) versus clinic DOT for tuberculosis: a systematic review and  
     meta-analysis of comparative effectiveness. BMC Infect Dis 2015; 15: 210. 
10. van Gorkom J, Mavhunga F, Omer O A, et al. TB control in Namibia 2002-2011: 
      progress and technical assistance. Open Infect Dis J 2013; 7 (Suppl. 1): 23-29. 
11. Republic of Namibia Ministry of Health and Social Services. National Guidelines for  
      the Management of Tuberculosis, Third Edition 2011, Windhoek, Namibia. 
12. Republic of Namibia Ministry of Health and Social Services. The National Strategic 
      Plan on Tuberculosis (TB): Medium Term Plan I (MTP-I) 2004-2009, 2004,  
      Windhoek, Namibia. 
13. Republic of Namibia Ministry of Health and Social Services. The National Strategic 
      Plan on Tuberculosis (TB): Medium Term Plan II (MTP-I) 2010-2015, 2010,  
      Windhoek, Namibia. 
14. Thiam S, LeFevre A M, Hane F, et al. Effectiveness of a strategy to improve  
      adherence to tuberculosis treatment in a resource-poor setting: a cluster  
      randomized controlled trial. JAMA 2007; 297: 380-386. 
15. Bernal J L, Cummins S, Gasparrini A. Interrupted time series regression for the  
      evaluation of public health interventions: a tutorial. Int J Epidemiol 2017; 46: 348- 
      355. 
16. Huynh G H, Klein D J, Chin D P, et al. Tuberculosis control strategies to reach the  
      2035 global targets in China: the role of changing demographics and reactivation  
      disease. BMC Med 2015; 13: 88. 
17. van Hest R, Ködmön C, Verver S, et al. Tuberculosis treatment outcome monitoring  
      in European Union countries: a systematic review. Eur Respir J 2013; 41: 635-643. 
18. Oxlade O, Piatek A, Vincent C, Menzies D. Modeling the impact of tuberculosis  
      interventions on epidemiologic outcomes and health system costs. BMC Public  
      Health 2015; 15: 141. 
19. Sterling T R, Lehmann HP, Frieden T R. Impact of DOTS with DOTS-plus on  
  
17 
      multidrug resistant tuberculosis and tuberculosis deaths: decision analysis. BMJ 
      2003; 326 (7389): 574. 
20. Chida N, Ansari Z, Hussain H. Determinants of default from tuberculosis treatment  
      among patients with drug-susceptible tuberculosis in Karachi, Pakistan: a mixed  
      methods study. PLoS One 2015; 10: e0142384.  
21. Tilahun G, Gebre-Selassie S. Treatment outcomes of childhood tuberculosis in  
      Addis Ababa: a five-year retrospective analysis. BMC Public Health 2016; 16: 612.  
22. Sinshaw Y, Alemu S, Fekadu A, Gizachew M. Successful TB treatment outcome  
      and its associated factors among TB/HIV co-infected patients attending Gondar  
      University Referral Hospital, Northwest Ethiopia: an institution based cross-sectional  
      Study. BMC Infect Dis 2017; 17: 132. 
23. Republic of Namibia Ministry of Health and Social Services. National Tuberculosis  
      and Leprosy  Programme Summary Report 2014-15, Windhoek, Namibia. 
24. Ahmad S, Mokaddas E. Tuberculosis: risk factors, drug resistance, rapid detection  
       and treatment. In: Walker S E, Martin D F, eds. Tuberculosis: Risk Factors, D 
      Resistance and Treatment. Hauppauge, NY: Nova Science Publishers, 2012: pp 1- 
      186. 
25. Choi R, Jeong B-H, Koh W-J, Lee S-Y. Recommendations for optimizing  
       tuberculosis treatment: therapeutic drug monitoring, pharmacogenetics, and 
       nutritional status considerations. Ann Lab Med. 2017; 37: 97-107. 
26. Waitt C J, Suire S B. A systematic review of risk factors for death in adults during  
       and after tuberculosis treatment. Int J Tuberc Lung Dis 2011; 15: 871-885.  
27. Ismail I, Bulgiba A. Determinants of unsuccessful tuberculosis treatment outcomes 
      in Malaysian HIV-infected patients. Prev Med 2013; 57 (Suppl.): S27-S30. 
28. Baker M A, Harries A D, Jeon C Y, et al. The impact of diabetes on tuberculosis  
      treatment outcomes: a systematic review. BMC Med 2011; 9: 81. 
29. Verbeeck R K, Günther G, Kibuule D, et al. Optimizing treatment outcome of first- 
      line anti-tuberculosis drugs: the role of therapeutic drug monitoring. Eur J Clin  
      Pharmacol 2016; 72: 905-916. 
30. Manosuthy W, Wiboonchutikul S, Sungkanuparph S. Integrated therapy for HIV and  
      tuberculosis. AIDS Res Ther 2016; 13: 22. 
  
18 
 
Supplement A  
 
Segmented regression model for treatment success, cure and completion rate  
 
          An interrupted time series analysis was carried out to assess the effectiveness of 
CB-DOTS strategy on TSR, CNR, cure and treatment completion rates for all cases. 
Interrupted time series analysis is a valuable study design for evaluating the 
effectiveness of population-level health interventions that have been implemented at a 
clearly defined point in time.15 In this design, pre-intervention regression level and trend 
of the outcome measure act as controls for the post-intervention segment.15 The 
intervention was the expansion of FB-DOTS to CB-DOTS in Namibia. The effective time 
for implementation of the CB-DOTS strategy was set at 2005, one year after the 
implementation of MTP-I. This considered a one-year phase-in period since a full cycle 
of completion of DOTS lasts between 6-8 months for a patient with drug sensitive TB 
and reporting of the treatment success rate in the subsequent year. The outcome 
variables were the TSR, defined as the percentage of patients who cured and 
completed DOT in a particular year under review, the treatment completion rate and the 
annual CNR.11 The impact of CB-DOTS on TSR, cure and completion rates, and 
covariates such as HIV prevalence, CB-DOTS and ART coverage was determined by 
WKHFKDQJHLQOHYHOȕ2) and WUHQGȕ2) in the treatment outcome in the pre and post- 
intervention period after 2005 by a segmented regression model using RStudio v3.3.2 
as detailed below.  
            The following segmented regression model was used to determine the level and 
trend changes in tuberculosis treatment success, cure and completion: 
Yt = E0 + E1T + E2 Xt + E3TXt + EwTXt + et 
Yt is the outcome, i.e. treatment success rate or case notification rate at time t, T is the 
time (in years) that elapsed since the start of the study, Xt is a dummy variable 
indicating the pre-intervention period (coded 0) or the post-intervention period (coded 
1); E0 estimates the baseline outcome at T=0; E1 is an estimate of the pre-intervention 
outcome trend (i.e. the change in outcome with time); E2 is an estimate of the change in 
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outcome immediately after the intervention, i.e. compared to the outcome at the end of 
the pre-intervention period; E3 estimates the change in the post-intervention outcome 
trend compared to the pre-intervention outcome trend; Ew estimates the impact of the 
wild point in 2004 (i.e the unexpectedly low TSR and cure rate, or unexpectedly high 
completion rate, in 2004 relative to preceding years) which was excluded from the final 
model; et represents the random variability not explained by the model. The TSR in 
2004 was modeled as a wild point (i.e. there was an abrupt drop in TSR in that year 
relative to the preceding years (1996-2004). This unexpected drop in TSR may have 
been due to the transition from the FB-DOTS to the CB-DOTS policy, the high incidence 
of TB and HIV in that year as well as programmatic challenges for switching to fixed-
dose combination anti-tuberculosis medicines. The impact of population time varying 
covariates such as TB incidence, HIV prevalence and ART (antiretroviral) coverage on 
TSR and/or CNR were modeled individually as EiTXi alongside the Yt parameters. 
Adjustment for serial autocorrelation was carried out by using the Durbin-Watson 
statistic and an autocorrelation parameter was included in the segmented regression 
model.  
 
Supplement B 
 
Facility-based and community-based DOTS in Namibia 
 
                   Namibia achieved a country-wide DOTS coverage at all public health 
facilities, that is 42 hospitals, 34 health centers and 244 clinics by 199612. Nonetheless, 
the geographical access to DOT was limited as many patients live too far away from 
clinics (upto 50 km) to come for daily clinic DOT and led to inadequate tracing of 
treatment interrupters. Still, there was hardly any provision of community-based DOT.12 
Furthermore, the high pill burden (i.e 9-12 tablets per day) of first-line single-drug DOT 
formulations compromised the adherence and the effectiveness of the medication, 
particularly among patients on co-medication for TB and HIV. Besides, sputum-smear 
examination services were insufficient at hospitals (i.e long distances between the 30 
laboratories and hospitals, irregular specimen collection and smear result time turn-
around time beyond 48 hours) and unavailable in health centers and clinics. This 
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negatively impacted on the utility of sputum-smear for diagnosis and treatment follow-
up.  Consequently, in 2004 Namibia reported the emergence of drug resistant TB (DR-
TB), the lowest TSR and highest CNR for tuberculosis.12 
    The community-based DOTS (CB-DOTS) strategy, designed to mitigate the 
persistently high CNR and low TSR despite a country-wide implementation of facility-
based DOTS between 1995-2004, and which was effectively implemented in Namibia in 
March 2005 under the first and second medium term plans (MTP-I, 2004-2009; MTP-II, 
2010-2015) for Tuberculosis and Leprosy constitutHVµWKHLQWHUYHQWLRQ¶LQWKHLQWHUUXSWHG
time series analysis. The strategic goal of CB-DOTS was to improve TB diagnosis, cure 
and treatment completion through universal access (i.e geographic and patient level) to 
high quality community-based tuberculosis care. In particular, the CB-DOTS aimed to 
increase TSR for all patient categories from 65% to 85% by 2009 and to 90% by 2015. 
To achieve these goals, CB-DOTS implementation framework designated the National 
Tuberculosis and Leprosy Programme (NTLP) and health districts (34) as the 
coordination and implementing units respectively, to work in partnership with up-to14 
community-based organisations (CBOs) implementing TB or HIV care. The budget for 
implementing CB-DOTS was funded by the Government of Republic of Namibia (51%), 
Global fund (19%) and USAID (3%), among others through sub-grants to the CBOs. 
This framework also paved way for the introduction of Fixed-Dose Combination (FDC) 
drugs for first-line tuberculosis treatment, CB-DOT training manual and national course, 
adoption of the WHO guidelines for TB treatment for supporters and universal access to 
high-quality low-cost DOT regimens, revision of TB guidelines to improve case 
management and community-based DOT cards to track treatment outcomes were 
introduced10,12.  By 2015, CB-DOTS coverage had scaled-up one pilot region (Omaheke 
in 2004) to 12 regions and 27 districts during MTP-I and to all 14 regions and 34 health 
districts during MTP-II, and a total of 529 community health workers (i.e. CHW: TB 
cases ~ 1:25 or 529/13147), were deployed. A team of community-based persons 
comprising of CHW (i.e community-DOT supervisors and facility and DOT nurses), DOT 
field promoters, and community-DOT supporters implement the CB-DOTS programme 
at each health district unit. The CBOs assist the district unit in early identification of TB 
cases and the provision of DOT in the community. The DOT-supporters such as 
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family/relatives or workplace peers or CHW directly observe the administration of the 
TB-medication at community DOT points, households and workplaces. For instance, in 
2015 in the Omaheke region there were, 954 DOT supporters, 858 supervisors and 
1189 DOT providers deployed. In addition, the access to quality of CB-DOTS services 
was expanded scaled-up during MTP-II (2010-2015), that is to all 14 regions and 34/34 
health districts, all 13 regional prisons, collaborative integration in all CBOs and sites 
implementing community-based HIV care, public-private workplace partnerships and 
mobile CB-DOT clinics. Also the quality of CB-DOTS was enhanced, through scale up 
quality assured bacteriology laboratories from 30 (1 lab per 67,000 people) in 2004 to 
36 out 80 in 2015 to increase case detection, a CB-DOTS training manual and WHO 
guideline for TB treatment supporters to standardize treatment with supervision and 
patient support, a system for effective supply and management of TB drugs as well as a 
monitoring and evaluation system to for effective measurement.   
 
 
Supplement C 
 
 
Prediction of the maximum possible treatment success rate under CB-DOTS  
 
          To estimate the maximum treatment success rate that could theoretically be 
expected based on the observed post-intervention treatment success rates, nonlinear 
regression analysis was carried out using the following model predicting the maximum 
outcome as a function of time after the intervention:  
 ܴܶܵ ൌ ܣ ൅ ܴܶܵ௠௔௫ ή ܶହܶ଴ ൅ ܶ  
 
in which A is the TSR level at the intervention estimated by the segmented regression 
model, TSRmax is the maximum treatment effect rate, T50 is the time at which the 
outcome is 50% of TSRmax, and T is the time (in years) after the intervention. For all 
statistical tests, a p-value of d0.05 was considered to be significant. 
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           Figure 5: The maximum effect model fitted the post-intervention treatment  
                           success rates (TSR) very well (r2 = 0.961) with a predicted  
                           maximum TSR of 92.4%. 
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